Immunizations, Immunoprophylaxis, and Chemoprophylaxis to Prevent Selected Infections

JAMA: The Journal of the American Medical Association

Volumn 257, Issue 18, 1987, Pages 2464-2470

  Laforce, F Marc ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BCG VACCINE; CHLOROQUINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A ANTIBODY; HEPATITIS B VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; TETANUS TOXOID;

CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG INDICATION; DRUG THERAPY; HUMAN; IMMUNIZATION; IMMUNOPROPHYLAXIS; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PREVENTION; PRIORITY JOURNAL; SHORT SURVEY; THERAPY;

ADULT; AGED; CHILD; FEMALE; HUMAN; IMMUNIZATION; IMMUNIZATION, PASSIVE; INFANT; INFECTION CONTROL; MALE; MIDDLE AGE; PREGNANCY; RISK; TOXOIDS; VACCINATION;

EID: 0023236344     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1987.03390180082028     Document Type: Article

References (55)

1. Advisory Committee on Immunization Practices: Diphtheria, tetanus, and pertussis: Guidelines for vaccine prophylaxis and other preventive measures. MMWR 1985;34:405-426.
2. Hinman AR, Koplan JP: Pertussis and pertussis vaccine: Reanalysis of benefits, risks, and costs. JAMA 1984;251:3109-3113.
3. Miller DL, Alderslade R, Ross EM: Whooping cough and whooping cough vaccine: The risks and benefits debate. Epidemiol Rev 1982;4:1-24.
4. Supplementary statement of contraindications to receipt of pertussis vaccine. MMWR 1984;33:169-171.
5. Nightingale EO: Recommendations for a national policy on poliomyelitis vaccination. N Engl J Med 1977;297:249-253.
6. Advisory Committee on Immunization Practices: Polysaccharide vaccine for prevention of Hemophilus influenzae type b disease. MMWR 1985;34:201-205.
7. Redmond SR, Pichichero ME: Hemophilus influenzae type b disease: An epidemiologic study with special reference to day-care centers. JAMA 1984; 252:2581-2584.
8. Peltola H, Kayhty H, Virtanen M, et al: Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984;310:1561-1566.
9. Advisory Committee on Immunization Practices: Update: Prevention of Haemophilus influenzae type b disease. MMWR 1986;35:170-180.
10. Band JD, Fraser DW, Ajello MA: Prevention of Haemophilus influenzae type b disease. JAMA 1984;251:2381-2385.
11. Tetanus—United States, 1982-1984. MMWR 1985;34:602-611.
12. Crossley K, Irvine P, Warren JB, et al: Tetanus and diphtheria immunity in urban Minnesota adults. JAMA 1979;242:2298-2300.
13. Weiss BP, Strassburg MA, Feeley JC. Tetanus and diphtheria immunity in an elderly population in Los Angeles County. Am J Public Health 1983;73: 802-804.
14. Advisory Committee on Immunization Practices: Prevention and control of influenza. MMWR 1985;34:261-275.
15. Meiklejohn G: Effectiveness of monovalent influenza A-prime vaccine during the 1957 influenza A-prime epidemic. Am J Hyg 1958;67:237-249.
16. Barker WH, Mullooly JP: Influenza vaccination of elderly persons: Reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980;244: 2547-2549.
17. Rubin FL: Prevention of influenza in the elderly. J Am Geriatr Soc 1982; 30:577-580.
18. Kaplan JE, Katona P, Hurwitz ES, et al: Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: Lack of an association with influenzae vaccination. JAMA 1982;248:698-700.
19. Consensus development conference panel: Amantadine: Does it have a role in the prevention and treatment of influenza? A National Institutes of Health Consensus Development Conference. Ann Intern Med 1980;92:256-258.
20. Oker-Blom N, Houi T, Leinikki P, et al: Protection of man from natural infection with influenza Hong Kong virus by amantadine: A controlled study. Br Med J 1970;3:676-678.
21. Centers for Disease Control: Pneumococcal polysaccharide vaccine: Recommendation of the Immunization Practices Advisory Committee. Ann Intern Med 1982;96:203-205.
22. Schwartz JS: Pneumococcal vaccine: Clinical efficacy and effectiveness. Ann Intern Med 1982;96:208-220.
23. Hirschmann JV, Lipsky BA: Pneumococcal vaccine in the United States: A critical analysis. JAMA 1981;246:1428-1432.
24. Austrian R, Douglas RM, Schiffman G, et al: Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976;89:184-194.
25. Bolan G, Broome CV, Facklam RR, et al: Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986;104:1-6.
26. Shapiro ED, Clemens JD: A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984;101:325-330.
27. Siber GR, Weitzman SZ, Aisenberg AC, et al: Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin’s disease. N Engl J Med 1979;299:442-448.
28. Linneman CC Jr, First MR, Schiffman G: Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 1981;141:363-370.
29. Hosea SW, Burch CG, Brown EJ, et al: Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet 1981;1: 804-807.
30. American Thoracic Society/Centers for Disease Control Statement: BCG vaccines for tuberculosis. Am Rev Respir Dis 1975;112:478-480.
31. Clemens JD, Chuong JJH, Feinstein AR: The BCG controversy: A methodological and statistical reappraisal. JAMA 1983;249:2362-2369.
32. American Thoracic Society/Centers for Disease Control: Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis 1983;127: 790-796.
33. Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis: A general review. Adv Tuberc Res 1970;17:28-106.
34. Cooperative study: Prophylactic gamma globulin for prevention of endemic hepatitis. Arch Intern Med 1971;128:723-738.
35. Woodson RD, Clinton JJ: Hepatitis prophylaxis abroad. JAMA 1969;209: 1053-1058.
36. Advisory Committee on Immunization Practices: Recommendations for protection against viral hepatitis. MMWR 1985;34:313-335.
37. Stokes J, Neefe JR: The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 1945;127:144-145.
38. Szmuness W, Stevens CE, Harley EJ, et al: Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-841.
39. Seeff LB, Wright EC, Zimmerman HJ, et al: Type B hepatitis after needle-stick exposure: Prevention with hepatitis B immune globulin: Final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978;88: 285-293.
40. Redeker AG, Mosley JW, Goeke DJ, et al: Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N Engl J Med 1975;293:1055-1059.
41. Perrillo RP, Campbell CR, Strang S, et al: Immune globulin and hepatitis B immune globulin: Prophylactic measures for intimate contacts exposed to acute type B hepatitis. Arch Intern Med 1984;144:81-85.
42. Maynard JE: Passive immunization against hepatitis B: A review of recent studies and comment on current aspects of control. Am J Epidemiol 1978;107: 77-86.
43. Postexposure prophylaxis of hepatitis B. MMWR 1984;33:285-290.
44. Beasley RP, Hwang LY, Stevens CE, et al: Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3:135-141.
45. Beasley RP, Hwang LY, Lee GC, et al: Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-1102.
46. Wong VCW, Ip HMH, Reesink HW, et al: Prevention of the HBsAg carrier status in newborn infants in mothers who are chronic carriers of HBsAg and HBsAg by administration of hepatitis B vaccine and hepatitis B immune globulin: Double-blind randomized placebo-controlled study. Lancet 1984;1: 921-926.
47. Advisory Committee on Immunization Practices: Meningococcal vaccines. MMWR 1985;34:255-259.
48. Mäkelä PH, Käyhty H, Weckström P, et al: Effect of group A meningococcal vaccine in army recruits in Finland. Lancet 1975;2:883-886.
49. Artenstein MS, Gold R, Zimmerly JG, et al: Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970;282:417-420.
50. Guttler RB, Counts GW, Avent CK, et al: Effect of rifampin and minocycline on meningococcal carrier rates. J Infect Dis 1971;124:199-204.
51. Cheever FS: The control of meningococcal meningitis by mass prophylaxis with sulfadiazine. Am J Med Sci 1945;209:74-80.
52. Nicholson KG, Turner GS: Studies with human diploid cell strain rabies vaccine and human antirabies immunoglobulin in man. Dev Biol Stand 1978;40:115-120.
53. Bahmanyar M, Fayaz A, Nour-Salehi S, et al: Successful protection of humans exposed to rabies infection: Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976;236: 2751-2754.
54. Prevention of malaria in travelers, 1982. MMWR 1982;31(suppl):1s-28s.
55. Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum. MMWR 1985;34:185-195.